Dr. Eric Padron, MD, PhD, is a Senior Member and Scientific Director in the Malignant Hematology Department at the H. Lee Moffitt Cancer Center, with a research focus in chronic myelomonocytic leukemia (CMML), clonal hematopoiesis, and chronic myeloid neoplasms. His translational laboratory seeks to identify and implement novel discoveries directly to the clinic. Although mechanistic studies to understand the molecular underpinnings of chronic myelomonocytic leukemia (CMML) constitute a large portion of his laboratory’s efforts, his laboratory singularly views these insights as tools for translation to the clinic to improve the management of patients with chronic myeloid neoplasms. This urgency is born out of Dr. Padron’s CMML clinic, in which most of his patients succumb to their disease.

He has been awarded several grants for his genomic studies in the MDS and CMML fields, including the American Society of Hematology Scholar Award, the Evans MDS Foundation Fellow Award, funding from the NCI to study the therapeutic candidacy of long noncoding RNAs, and a large MDS Foundation grant to study molecular aspects of CMML in 1,000 patients. Dr. Padron has successfully translated his lab discoveries into several trials in the CMML clinic. This is exemplified by his bench-to-bedside efforts that have led to the successful completion of phase 1 and 2 trials testing ruxolitinib in CMML. Dr. Padron has published over 215 peer-reviewed manuscripts in the area of myeloid malignancies.

Importantly, Dr. Padron was awarded an R37 NCI grant to develop a CMML PDX model that can recapitulate the human condition. In this context, the Padron lab has generated